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Neutral ceramidase (NCDase) and sphingosine kinases
(SphKs) are key enzymes regulating cellular sphingosine-1-
phosphate (S1P) levels. In this study we found that stress
factor-induced apoptosis of rat renal mesangial cells was
significantly reduced by dexamethasone treatment.
Concomitantly, dexamethasone increased cellular S1P levels,
suggesting an activation of sphingolipid-metabolizing
enzymes. The cell-protective effect of glucocorticoids was
reversed by a SphK inhibitor, was completely absent in
SphK1-deficient cells, and was associated with upregulated
mRNA and protein expression of NCDase and SphK1.
Additionally, in vivo experiments in mice showed that
dexamethasone also upregulated SphK1 mRNA and activity,
and NCDase protein expression in the kidney. Fragments
(2285, 1724, and 1126bp) of the rat NCDase promoter linked
to a luciferase reporter were transfected into rat kidney
fibroblasts and mesangial cells. There was enhanced NCDase
promoter activity upon glucocorticoids treatment that was
abolished by the glucocorticoid receptor antagonist RU-486.
Single and double mutations of the two putative
glucocorticoid response element sites within the promoter
reduced the dexamethasone effect, suggesting that both
glucocorticoid response elements are functionally active and
required for induction. Our study shows that glucocorticoids
exert a protective effect on stress-induced mesangial cell
apoptosis in vitro and in vivo by upregulating NCDase and
SphK1 expression and activity, resulting in enhanced levels of
the protective lipid second messenger S1P.
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Sphingomyelin is the most abundant sphingolipid in cellular
membranes, in which it serves not only as a structural
component, but also as a precursor for various sphingolipid
signaling molecules, including ceramide and sphingosine-1-
phosphate (S1P). These two bioactive lipids regulate a variety
of physiological and pathophysiological processes such as
growth and differentiation, cell migration and adhesion,
apoptosis, and inflammatory reactions.1–5
Upon exposure of cells to various stress factors, including
proinflammatory cytokines, sphingomyelinases are activated
and hydrolyze sphingomyelin to generate ceramide. Cera-
mide is further degraded by ceramidases to sphingosine that,
in turn, serves as a substrate for sphingosine kinases to
generate S1P. In contrast to ceramide and sphingosine, both
of which can trigger an apoptotic cell response, S1P exerts an
effect to counter-balance this response and stimulates cell
proliferation and protects cells from apoptosis. This has
led to the hypothesis of a cellular sphingolipid rheostat in
which ceramide and S1P counter-regulate each other’s
functions.1,3,6
As sphingosine is not produced by de novo synthesis,7 the
activity of ceramidases (N-acylsphingosine amidohydrolase,
ASAH) is crucial for limiting the ceramide-induced signaling
as well as for the generation of sphingosine and S1P.
Ceramidases are classified into three different groups
according to their catalytic pH optimum, namely acid,
alkaline, and neutral ceramidases.8 The acid ceramidase is
localized in the lysosomes9 and its genetic mutation causes
Farber’s disease, a disorder in which ceramide excessively
accumulates in lysosomes.10 The alkaline ceramidase is
localized in the endoplasmic reticulum and Golgi, but its
physiological role is hardly understood.11 The neutral
ceramidase (NCDase) has been cloned from various species8
and the primary sequence among the species is highly
conserved. A predominant localization of NCDase at the
plasma membrane has been reported.12,13 To date, only little
is known about the transcriptional and posttranscriptional
regulation of NCDase. It has been shown that proinflamma-
tory cytokines, such as interleukin-1b and tumor necrosis
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factor-a (TNF-a), increased the NCDase expression in
hepatocytes14 and mesangial cells,15,16 whereas nitric oxide
decreased the NCDase expression levels by a proteasomal
degradation route.17,18 In addition, under diabetic conditions
the expressions and activities of NCDase and sphingosine
kinase were increased in kidney, and increased S1P
concentrations were proposed to trigger for hyperprolifera-
tion of mesangial cells in diabetic glomeruli.19 Recently,
the promoter of the mouse asah 2 gene was cloned20 and
revealed potential binding sites for GATA-2, C/EBP, and
HNF3, although the functionality of these sites remained
undetermined.
Sphingosine kinases (SphKs) are the critical enzymes
directly generating S1P. SphKs exist as two subtypes,21 SphK1
and SphK2, although the differential physiological functions
of these two subtypes are presently unclear. At least, SphK1
has been attributed a key function in cell proliferation and
migration, and an upregulation of SphK1 mRNA is reported
for several forms of tumor tissues and cell lines.21–24 In
contrast, SphK2 rather exerts a pro-apoptotic function based
on cellular transfection experiments.25
In this study, we used rat renal mesangial cells and showed
that glucocorticoids protect mesangial cells from stress-
induced apoptosis. This protective effect is because of a
coordinated upregulation and activation of NCDase and
SphK1 that resulted in an increased cellular S1P level. In
addition, in kidneys of dexamethasone-treated mice, SphK1
expression and activity, and NCDase expression were
enhanced in glomeruli or whole kidney extracts. Further-
more, we showed that the rat NCDase promoter contains two
functional glucocorticoid-response element (GRE) sites that
contribute to the enhancing effect of glucocorticoids on
NCDase gene transcription.
RESULTS
Dexamethasone protects renal mesangial cells from
apoptosis
Stimulation of rat renal mesangial cells with staurosporine or
TNF-a plus cycloheximide is well known to induce
apoptosis.15,26–28 Accordingly, increased DNA fragmentation
was observed after 16 h of stimulation with these factors
(Figure 1a) when using a DNA fragmentation enzyme-linked
immunosorbent assay. In the presence of dexamethasone,
which exerts its effect by binding to the glucocorticoid
receptor (GR) that is expressed in mesangial cells (Figure 1a,
inset), a significantly reduced DNA fragmentation occurred
(Figure 1a). To quantify the amount of apoptotic cells, we
additionally performed flow cytometry to determine the
amount of cells in the subG1 phase, which is considered to
represent apoptotic cells. In untreated cells, we found
5.9±1.5% apoptotic cells that increased to 50±2% after
16 h of staurosporine treatment. The inhibiting effect of
dexamethasone was reversed in the presence of the GR
antagonist RU-48629 (Figure 1b), indicating that the
protective effect is mediated by the GR receptor. Furthermore,
a panel of other glucocorticoids, including betamethasone,
hydrocortisone, fludrocortisone, and the mineralocorticoide
aldosterone, which also bind to the GR, exerted a similar
inhibitory effect on staurosporine-induced apoptosis (Figure 1c).
Interestingly, the protective effect of glucocorticoids on
staurosporine-triggered apoptosis was also reversed by a
SphK1 inhibitor, SKI II22 (Figure 1d), suggesting that SphK1
is involved in the protective action of glucocorticoids. In an
additional approach, we used mouse mesangial cells isolated
from either wild-type or SphK1 knockout mice. In wild-type
mesangial cells, staurosporine triggered a marked increase of
apoptosis, which was again reduced in the presence of
dexamethasone (Figure 2). In SphK1 knockout cells, the
staurosporine-induced apoptosis was even higher when
compared with the wild-type cells, which is consistent
with the hypothesis that SphK1 is a protective enzyme.
Remarkably, dexamethasone had no protective effect in these
SphK1 knockout cells (Figure 2).
Dexamethasone stimulates S1P generation in rat renal
mesangial cells
As S1P has recently been attributed an anti-apoptotic
capacity,3,5,30 we speculated that glucocorticoids may alter
the cellular levels of this sphingolipid second messenger. To
this end, cellular S1P levels were quantified by mass
spectrometry. As seen in Figure 3, the cellular S1P
concentration was very low, but significantly increased upon
dexamethasone treatment and was abolished in the presence
of RU-486, thus suggesting that either the S1P-generating
pathway is activated or the S1P-metabolizing pathways are
inhibited.
Therefore, we next analyzed the activity of SphK1 upon
dexamethasone treatment. Stimulated cell lysates were taken
for an in vitro kinase activity assay using sphingosine as a
substrate. Both concentrations of dexamethasone tested (that
is, 100 and 300 nM) led to a time-dependent increase in
SphK1 activity. In parallel to the increased SphK1 activity
(Figure 4a), SphK-1 protein expression was also increased
(Figure 4b) and this was preceded by an upregulated mRNA
expression of SphK1 (Figure 4c).
As sphingosine is normally not stored in the cell, we
analyzed whether the sphingosine-generating enzyme, that is,
the NCDase, is also regulated by glucocorticoids. As seen in
Figure 5, NCDase mRNA (Figure 5a) and protein expression
(Figure 5b) is upregulated by dexamethasone treatment. Two
forms of NCDase protein have been described in rat kidney: a
133 kDa Golgi form and a 113 kDa endoplasmic reticulum
form.31 Notably, dexamethasone only upregulated the
113 kDa endoplasmic reticulum form. In contrast, the acid
ceramidase was not upregulated by dexamethasone (data not
shown).
In a next step we analyzed whether the glucocorticoid-
mediated upregulation of the ceramidase/SphK1 pathway is
also occurring in vivo. To this end, we treated mice for 24 h
with dexamethasone (10mg/kg) and harvested kidneys and
prepared protein extracts from whole kidney and also
isolated glomeruli from these kidneys for RNA extraction.
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As seen in Figure 6a, SphK1 mRNA expression is significantly
enhanced in the glomeruli of the dexamethasone-treated
mice. In addition, when measuring SphK1 activity in whole
kidney extracts, an increase in the same range was found
(Figure 6b). Finally, NCDase protein expression in whole
kidney lysates was also upregulated (Figure 6c).
Dexamethasone exerts an effect through GREs in the rat
NCDase promoter sequence
We cloned a 2258-bp fragment of the rat NCDase promoter
and two shorter fragments of 1724 and 1126 bp size,
respectively. These fragments were fused to a luciferase
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Figure 1 | Effect of dexamethasone on stress-induced DNA
fragmentation in renal mesangial cells. (a) Quiescent mesangial
cells were preincubated for 1 h with either vehicle () or
dexamethasone (dex, 300 nM, þ ) before stimulation for 16 h with
either vehicle (Co), staurosporine (stauro, 30 nM), or tumor necrosis
factor-a (TNF-a; 1 nM) plus cycloheximide (10mg/ml) (TNF-a/CHX).
The inset shows the protein expression of the 95 kDa
glucocorticoid receptor (GR) in lysates of rat mesangial cells (MCs)
by western blot analysis. (b) Cells were treated for 16 h with stauro
(30 nM), stauroþdex (300 nM), or stauroþdexþ RU-486 (RU, 1 mM).
(c) Cells were treated with vehicle (Co) or stauro (30 nM) in the
absence () or presence of dex, betamethasone (bet),
hydrocortisone (hyd), fludrocortisone (flu), or aldosterone (ald)
(all at 300 nM). (d) Cells were treated for 16 h with vehicle (Co),
SKI II (SKI, 10mM), stauro (30 nM), stauroþbet (300 nM), or
stauroþbetþ SKI (10 mM). DNA fragmentation was analyzed as
described in the Materials and Methods section. Results are
expressed as percentage of control values and are means±s.e.m.
(n¼ 6 in a, n¼ 3 in b–d). ***Po0.001 considered statistically
significant when compared with the unstimulated control values;
###Po0.001 when compared with the staurosporine-stimulated
values; yPo0.05 when compared with the TNF-a plus
cycloheximide-stimulated values; 1Po0.05, 11Po0.01 when
compared with the stauro plus dex/bet-stimulated values.
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Figure 2 | Effect of dexamethasone on stress-induced
apoptosis in sphingosine kinase 1 (SphK1) knockout mouse
mesangial cells. Mesangial cells isolated from either wild-type
C59BL6 mice (wt-mMC, open bars) or SphK1-deficient mice
(SphK1ko mMC, closed bars) were treated for 16 h with either
vehicle (Co), staurosporine (stauro, 30 nM), staurosporine (30 nM)
plus dexamethasone (300 nM) (stauroþdex), or dexamethasone
alone (300 nM). Cells were taken for flow cytometry to determine
the number of cells in the sub G1 phase. Results are expressed as
percentage of apoptotic cells and are means±s.d. (n¼ 3).
***Po0.001 considered statistically significant when compared
with the vehicle-treated wt values; ###Po0.001 when compared
with the staurosporine-stimulated values.
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reporter construct and transfected into normal rat kidney
fibroblast (NRK) cells and rat renal mesangial cells. As seen in
Figure 7a, in NRK cells, dexamethasone was able to stimulate
the activity of all promoter fragments. In the presence of
RU-486, the dexamethasone-triggered NCDase promoter
activation was completely abolished in all fragments
(Figure 7a). A similar stimulating effect of dexamethasone
and reversing effect of RU-486 was also observed in rat
mesangial cells (Figure 7b). As rat mesangial cells show a very
low transfection efficiency, we used NRK cells for further
studies. Other glucocorticoids were tested such as beta-
methasone, hydrocortisone, and fludrocortisone. All these
drugs exerted a similar stimulating effect on NCDase
promoter activity (Figure 8). As the promoter sequence
contained two putative GREs at position –1337 bp (GRE1)
and at –890 bp (GRE2), we generated deletion mutants of the
1724 bp fragment. When the GRE1 site was deleted (DGRE1),
dex could still activate the promoter although to a
significantly reduced degree (Figure 9). When both sites
were deleted (DGRE1þ 2), the dex effect was completely
abolished (Figure 9), suggesting that both sites are essential
for the glucocorticoid effect.
DISCUSSION
In the past decades, glucocorticoids have been extensively
studied because of their potent and versatile pharmacological
profile. Many studies have meanwhile proven that glucocor-
ticoids have either pro- or anti-apoptotic capacities depend-
ing on the tissue and cell type that they exert an effect upon.
An induction of apoptosis is mainly observed in hemato-
poietic and immune cells.32 In contrast, a death protective
effect has been characterized for epithelial cells, fibroblasts,
endothelial cells, and hepatocytes.33–35 Although dexamethasone
was shown to suppress (1) the upregulation of proapoptotic
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mesangial cells were stimulated for 16 h with either vehicle (),
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1 mM). The cellular sphingolipid concentrations were quantified by
liquid chromatography-coupled mass spectrometry (LC/MS/MS)
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when compared with the control samples; ##Po0.01 significant
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Figure 4 | Effect of dexamethasone on sphingosine kinase 1
(SphK1) activity, mRNA, and protein expression in renal
mesangial cells. (a) Quiescent mesangial cells were stimulated for
the indicated time periods with either vehicle (triangles), or
100 nM (Dex; open circles), or 300 nM (Dex; closed circles) of
dexamethasone (Dex). Protein extracts containing equal amounts
of proteins were taken for an in vitro SphK1 activity assay as
described in the Materials and Methods section. Data are
expressed as percentage of control and are means±s.e.m. (n¼ 3).
*Po0.05, **Po0.01 considered statistically significant when
compared with the vehicle-stimulated values. (b, c) Cells were
stimulated for 24 h with either vehicle (Co) or 100 nM or 300 nM of
dexamethasone (dex). Thereafter, protein (b) or RNA (c) was
extracted. Protein extracts were separated by sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to nitrocellulose, and subjected to western blot
analysis using a specific antibody against SphK1 at a dilution of
1:2000 or against b-actin at a dilution of 1:1000. Data in b are
representative of three independent experiments. RNA was
subjected to quantitative PCR analysis using specific primers of rat
SphK1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Data in c are expressed as percentage of control values and are
means±s.e.m. (n¼ 3). *Po0.05, **Po0.01 considered statistically
significant when compared with the vehicle-stimulated values.
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members of the Bcl-2 family such as Bcl-xs and Bak
36,37
and (2) the downregulation of anti-apoptotic factors
such as Bcl-xL and members of the inhibitor of apoptosis
protein family evoked by TNF-a,37,38 the detailed anti-
apoptotic mechanism of glucocorticoids, particularly the
signaling pathways involved, still remains to be fully
elucidated.
In this study, we show for the first time that glucocorti-
coids have a protective effect on stress-induced apoptosis of
glomerular mesangial cells. This action crucially involves an
activation of the sphingomyelin signaling module accom-
panied by a coordinated expression and stimulation of
NCDase and SphK1 activities, which in turn result in
increased cellular S1P levels and protection from apoptosis.
Indeed, glucocorticoids have been evaluated as renopro-
tective compounds in various experimental and clinical
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Figure 6 | In vivo effect of dexamethasone on sphingosine
kinase (SphK1) mRNA and activity, and neutral ceramidase
(NCDase) expression in mice. C57BL6 mice were injected
intraperitoneally (i.p.) with either phosphate-buffered saline (PBS)
as control, or with dexamethasone (dex, 10mg/kg) for 24 h.
Thereafter, kidneys were harvested and taken for isolation of
glomeruli by using a differential sieving method. (a) RNA was
extracted and taken for quantitative PCR analysis of SphK1 and
18S RNA. Protein lysates were taken for (b) SphK1 activity or for (c)
NCDase protein expression by western blot analysis. Results are
expressed as percentage of control and are means ± s.d. (n¼ 5).
*Po0.05, **Po0.01 considered statistically significant compared
with phosphate-buffered saline (PBS)-treated mouse values by a
two-tailed t-test.
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Figure 5 | Effect of dexamethasone on neutral ceramidase
(NCDase) mRNA and protein expression in renal mesangial
cells. Quiescent rat renal mesangial cells were stimulated for 20 h
with either vehicle (Co) or the indicated concentrations of
dexamethasone (dex). Thereafter, RNA or protein was extracted.
(a) The RNA was subjected to quantitative PCR analysis of NCDase.
(b) Protein extracts were separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose, and subjected to western blot analysis using a
polyclonal antiserum against NCDase at a dilution of 1:1000.
Bands corresponding to the 113 kDa NCDase and b-actin were
densitometrically evaluated and the ratio between NCDase and
b-actin was calculated and depicted as relative NCDase expression
in a graph. Data in a and b are expressed as percentage of control
values and are means±s.e.m. (n¼ 3). *Po0.05, **Po0.01
considered statistically significant when compared with the
vehicle-stimulated values. The inset in b shows one representative
immunoblot.
874 Kidney International (2010) 77, 870–879
or ig ina l a r t i c l e A Fo¨rster et al.: Glucocorticoids act cytoprotectively by increasing S1P in MC
settings.39,40 They also exert cardio- and neuroprotective
actions in the course of ischemic injury by triggering the
augmentation of blood flow.41,42 The latter effects were
suggested to be due to a phosphorylation of endothelial nitric
oxide synthase by the phosphatidylinositol 3 kinase/protein
kinase B pathway.
Dexamethasone was reported to have a direct protective
effect on glomerular endothelial cells exposed to TNF-a or
lipopolysaccharide,33 and prevents apoptosis of podocytes
stimulated with puromycin.34 That this protection also
extends to mesangial cells, as reported in this study, may
explain why glucocorticoids have been used successfully to
treat numerous clinical conditions affecting the kidney
glomerulus.
Collectively, these observations provide strong evidence
that targeting of resident glomerular cells may be as
important for the therapeutic action of glucocorticoids as
the anti-inflammatory and immunosuppressive action on
lymphocytes.
Typically, glucocorticoids bind to the ligand-binding
domain of the GR to initiate its nuclear translocation and
subsequent interaction with conserved palindromic DNA
sequences denominated as GREs. Binding to these cis-acting
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Figure 7 | Effect of dexamethasone and RU-486 on rat neutral
ceramidase (NCDase) promoter activity in renal mesangial
cells and fibroblasts. (a) Normal rat kidney fibroblasts were
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fragment of the rat NCDase promoter plus the plasmid coding for
Renilla luciferase. (b) Rat mesangial cells were co-transfected for
6 h with the 2285 bp fragment plus the plasmid coding for Renilla
luciferase. Cells were then stimulated for 20 h with either vehicle
(Co), dexamethasone (Dex, 100 nM), or dexamethasone plus RU-
486 (Dexþ RU-486; 1 mM) as indicated. The ratio between firefly
and Renilla luciferase activity was calculated. Relative luciferase
activities are expressed as fold induction of control values and are
means±s.d. (n¼ 3). *Po0.05, **Po0.01 considered statistically
significant when compared with the vehicle-stimulated values.
#Po0.05, ##Po0.01 considered statistically significant when
compared with the dexa-stimulated values.
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Figure 8 | Effect of various glucocorticoids on rat neutral
ceramidase (NCDase) promoter activity. Normal rat kidney
fibroblasts were co-transfected for 6 h with either the 2285, 1724,
or 1126 bp fragment of the rat NCDase promoter plus the plasmid
coding for Renilla luciferase, and then stimulated for 20 h with
either vehicle (Co) or 100 nM of betamethasone (bet),
hydrocortisone (hyd), or fludrocortisone (flu). The ratio between
firefly and Renilla luciferase activity was calculated. Relative
luciferase activities are expressed as percentage of control values
and are means±s.d. (n¼ 3). *Po0.05, **Po0.01, ***Po0.001
considered statistically significant when compared with the
vehicle-stimulated values.
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Figure 9 | Effect of glucocorticoid-responsive element (GRE)
deletions on dexamethasone-stimulated neutral ceramidase
(NCDase) promoter activity. Normal rat kidney fibroblasts were
co-transfected for 6 h with the wild-type 1724 bp construct (wt),
the GRE1 mutated construct (DGRE1), or the GRE1 plus GRE2
mutated construct (DGRE1þ 2) as described in the Materials and
Methods section. Thereafter, cells were stimulated for 16 h with
either vehicle (Co) or dexamethasone (Dex, 100 nM). The ratio
between firefly and Renilla luciferase activity was calculated.
Relative luciferase activities are expressed as percentage of the
respective control values and are means±s.d. (n¼ 3–4). **Po0.01
considered statistically significant when compared with the
vehicle-treated wt values; ##Po0.01 compared with the dex-
treated wt values.
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promoter elements leads to transcriptional activation of
glucocorticoid-responsive genes (‘transactivation’). In con-
trast to transactivation, most inhibitory actions exerted by
glucocorticoids arise from the mutual interaction between
the GR and transcriptional activators such as activator
protein 1 or nuclear factor-kB. This interaction occurs
independent from DNA binding and is termed ‘trans-
repression’.43,44 Pharmacologists use this information to
separate transrepression from transactivation to yield the
so-called dissociated glucocorticoids that may allow to reduce
the side effects of an anti-inflammatory therapy with
glucocorticoids.45,46
Despite our extensive knowledge about glucocorticoid-
induced gene regulation, the global networks regulated by GR
remain unknown. Recently, Phuc Le et al.47 reported on 1300
differentially expressed genes in mouse liver exposed to
glucocorticoids. Subsequently executed genome-wide loca-
tion analysis on chromatin from the same livers identified
more than 300 promoters that are bound by the GR. Finally,
53 genes were identified to be functionally regulated by
ligand-occupied GR. The list contains many genes that are
known or suspected GR targets, but not many signaling
devices were identified, as these usually are expressed at low
levels and require only subtle changes in expression levels for
functionality. Not surprisingly therefore, NCDase and SphK1
were missed in this study. An alternative powerful approach
is differential proteomic analysis that permits identification
of protein modifications and of translational regulation that
is not addressable by genomic analysis. The latter approach
has been used by Ransom et al.48 to identify 92 proteins in
murine podocytes that are differentially regulated by
dexamethasone. Among these, three proteins known to
protect cells from injury were found to be upregulated by
dexamethasone, comprising ciliary neurotrophic factor,
aB-crystallin, and heat shock protein 27. Again, besides
known factors, such as metabolic enzymes, antioxidant
enzymes, or actin cytoskeletal proteins, only few signaling
devices and no sphingolipid-metabolizing enzymes were
detected. It appears clear that such lists always remain
incomplete. As glucocorticoids exert different effects on the
many organ systems of the body, it is highly likely that the
functional targets of GR are different in each case. In
addition, glucocorticoids exert many posttranscriptional and
posttranslational actions49 and show further nongenomic
modes of action50 that alter protein functions profoundly.
In contrast, our strategy of identifying glucocorticoid
targets was hypothesis driven. Considering the central role of
the sphingomyelin signaling module in apoptosis and cell
survival in many different cellular systems, we felt that it is
worthwhile to analyze whether glucocorticoids alter the
expression of any of the key regulators of this pathway.
Especially the two sphingolipids, ceramide and S1P, have
been attributed a key regulatory function in the cell by
building a so-called cellular rheostat that determines cell
growth and death.3 In addition, in terms of inflammatory
mechanisms the balance between ceramide and S1P appears
to be a critical factor that determines a pro- or anti-
inflammatory outcome.51 Strikingly, we observed in renal
mesangial cells that glucocorticoids coordinately upregulated
the S1P-generating enzymes, NCDase and SphK1. The
subsequent marked increase in the protective mediator S1P
delivered survival signals to the cells and reduced TNF-a/
cycloheximide- or staurosporine-triggered apoptosis. Block-
ing SphK1 activity by the selective inhibitor, SKI II, reverted
the protective effects of dexamethasone, suggesting that
generation of S1P is a crucial step in the anti-apoptotic action
of glucocorticoids. In addition, when mouse mesangial cells
were used that had genetically knocked out the SphK1, not
only the staurosporine effect on apoptosis was accelerated,
but also the protective effect of dexamethasone was blunted.
The transcriptional regulation of NCDase expression by
glucocorticoids reported in this study can be attributed to
two GREs in the promoter region at –1337 bp and at –890 bp
within the NCDase gene. This is obvious from deletional
and mutational analysis of various promoter constructs
(Figures 7–9) and further supported by the action of the GR
antagonist RU-486 (Figure 7a and b). Whether SphK1
expression is also driven by a classical GR/GRE interaction
remains to be established in future investigations.
Collectively, our data reveal precise and valuable details of
how glucocorticoids affect a major signaling device, the
sphingolipid rheostat, that is used in renal cells to switch
between survival and death signals. Expressional regulation
of signaling molecules, such as NCDase and SphK1, by rather
conventional modes through GR/GRE-driven gene expres-
sion may have long-lasting effects on cellular behavior that
complement rapid non-genomic signaling events evoked by
glucocorticoids.50 This study offers new facets of action of
long-known drugs that may provide ways to better under-
stand what the term ‘pleiotropic’ means in the context of
glucocorticoids’ action. Eventually, this may also help to pave
the way for designing novel SEGRAs (selective glucocorticoid
receptor agonists) with an improved benefit-to-risk ratio.
MATERIALS AND METHODS
Chemicals
All glucocorticoids, mineralocorticoids, RU-486, SKI II, staurospor-
ine, and cycloheximide, and TRI-reagent were from Sigma-Aldrich
Fine Chemicals (Deisenhofen, Germany); NBD-coupled C12-
ceramide (N-C12-NBD-D-erythro-sphingosine) was from Biozol
Diagnostica Vertrieb GmbH (Eching, Germany); and Lipofectamine
and all cell culture nutrients were from Gibco Invitrogen (Karlsruhe,
Germany).
Generation of antibodies
The antibodies against neutral ceramidase and SphK1 were
generated and characterized as previously described.17,23
Cell culture
Rat renal mesangial cells were isolated and characterized as
described previously.52,53 For the experiments in this study, passages
9–20 were used. NRK fibroblasts (American Type Culture Collection,
Rockville, MD) were cultured in modified Eagle’s minimum
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essential medium supplemented with 5% fetal calf serum and
antibiotics. Mouse mesangial cells were isolated from kidneys of
C57BL6 mice or SphK1-deficient mice and cultivated as previously
described.28
Cell stimulation and western blot analysis
Cells were stimulated with the indicated substances in Dulbecco’s
modified Eagle medium containing 0.1mg/ml of fatty acid-free
bovine serum albumin. To stop the reaction, the medium was
removed, and the cells were homogenized and processed exactly as
previously described.17 Lysates, 50–100 mg, were separated by sodium
dodecylsulfate-polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes, and western blot analysis was performed
as previously described.17,23
Sphingolipid quantification by liquid chromatography-
coupled mass spectrometry
In six-well plates, 106 cells were stimulated as indicated. Cell
monolayers were then scraped in pure methanol containing an
internal C17-S1P standard and subjected to lipid extraction as
described by Bligh and Dyer.54 Lipids were redissolved in
dimethylsulfoxide containing 2% HCl and taken for liquid
chromatography-coupled mass spectrometry analysis exactly as
previously described.28
NCDase activity assay
Stimulated mesangial cells were scraped and lysed as described
above. The NCDase activity assay was performed according to
Galadari et al.55 A total of 100 mg protein lysate dissolved in 200 ml
lysis buffer was incubated with 0.2mmol NBD-coupled C12-
ceramide (N-C12-NBD-D-erythro-sphingosine) for 2 h at 37 1C.
Reaction was stopped by addition of 200 ml chloroform/methanol
(1:1, v/v). For phase separation, samples were centrifuged for 10min
at 13 000 g and 100 ml of the organic phase was taken and dried using
a vacuum concentrator. Lipids were dissolved in 25 ml chloroform/
methanol (2:1, v/v) and spotted on to thin-layer chromatography
plates. The cleaved product NBD-dodecanoic acid was separated by
developing the plate in chloroform/methanol/25% ammonium
hydroxide (90:30:0.5, v/v). The thin-layer chromatography plate
was scanned using PharosFX (Bio-Rad, Munich, Germany) and
C-12 NBD-fatty acids were analyzed using Quantity One 1-D
Analysis Software.
Sphingosine kinase activity assay
In vitro SphK1 activity assay was performed exactly as described
previously.23
Cell transfections and NCDase promoter studies
Different NCDase promoter fragments with sizes of 2285, 1724, and
1126 bp were cloned from rat genomic DNA (Novagen, Darmstadt,
Germany) by PCR using the same reverse primer: 50-CCGCTCGAG
GAGTCCAAATG-30 and the following forward primers: 2285 bp: 50-
CCGACGGGTGATGAAGCTG-30; 1724 bp: 50-CCGACGCGTCTAG
CACGTGTG-30; and 1126 bp: 50-CCGACGCGTGTTTGCTACTAT
GAC-30. The NCDase promoter fragments were fused into
the luciferase reporter gene-containing vector pGL3 (Promega,
Mannheim, Germany). NRK or rat mesangial cells were cultured in
12-well plates and transfected in serum-free media with 150 ng of
reporter plasmid DNA and 30 ng of Renilla luciferase reporter
plasmid using Lipofectamine (fibroblasts) or Effectene (mesangial
cells). After 6 h, the cells were stimulated as indicated in the figure
legends. To measure NCDase promoter activity, a luciferase reporter
gene assay was performed using a Lumat LB9507 luminometer
(Berthold Detection Systems, Pforzheim, Germany). Values for
NCDase promoter activity were calculated from the ratio of firefly to
Renilla luciferase activities and expressed as a percentage of control.
Site-directed mutagenesis of the NCDase promoter
Site-directed mutagenesis of two putative GREs, GRE1 (mutation of
–1339 to –1336 bp) and GRE2 (mutation of 891 to –889 bp), in the
NCDase promoter was carried out with the ‘QuickChange
Site-Directed Mutagenesis Kit’ (Stratagene Agilent Technologies,
Waldbronn, Germany). The primer pair (mutation sites are
underlined) used for DGRE1 was forward: 50-CAGGTCTCAAAGA
CCAAAGAAAGACATTAGCATCCTGATGTAACAGGAAAG-30 and
reverse: 50-CTTTCCTGTTACATCAGGATGCTAATGTCTTTCTTTG
GTCTTTGAGACCTG-30; and the primer pair for DGRE2 was
forward: 50-TCCTCTTCACAGCTGCTTAGACATCAGTCTCCAAG
AGGAGGAAAA-30 and reverse: 50-TTTTCCTCCTCTTGGAGAC
TGATGTCTAAGCAGCTGTGAAGAGGA-30. The mutations were
confirmed by DNA sequencing.
Quantitative real-time PCR (TaqMan)
Total RNA, 1 mg, isolated with TRI-Reagent was used for reverse
transcriptase-PCR (RevertAid First strand synthesis kit, Fermentas,
St Leon–Roth, Germany) using an oligo (dT) primer for amplifica-
tion. The real-time PCR reaction was carried out in 96-well PCR
plates from Applied Biosystems Applera (Darmstadt, Germany).
Probes and primers for rat NCDase, SphK1, and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) were obtained from
Applied Biosystems. The reporter dyes chosen were 6-FAM and VIC.
As PCR-Mix, Absolute QPCR low Rox Mix from Abgene (Dreieich,
Germany) was used. The run was performed on the Applied
Biosystems 7500 Fast Real-Time PCR System. The cycling condi-
tions were as follows: 95 1C for 15min (1 cycle), 95 1C for 15 s,
and 60 1C for 1min (40 cycles). 7500 Fast System SDS Software
from Applied Biosystems was used to analyze real-time and end
point fluorescence.
Determination of DNA fragmentation
Apoptosis was detected by measuring the appearance of cytoplasmic
histone-associated DNA fragments by photometric enzyme-linked
immunosorbent assay (Roche Diagnostics, Mannheim, Germany).
The preparation of cell lysates and the assay procedures were
performed according to the manufacturer’s protocol. Alternatively,
the amount of apoptotic cells was quantified by flow cytometric
analysis of DNA fragments residing in the subG1 phase. In brief,
stimulated cells were detached by trypsin/EDTA and fixed in 70%
ethanol for 16 h at 20 1C. Cells were washed with 38mM sodium
citrate and incubated for 30min with 10 mg/ml propidium iodide
and 10 mg/ml RNase A. Cells were analyzed by flow cytometry
for DNA content using a FACS Calibur (Becton & Dickinson,
San Jose, CA, USA).
Animal experiments
All animal experiments were conducted in accordance with the
German Animal Protection Law and were approved by the ethics
review committee of the District Governments of Darmstadt,
Germany. Male C57BL6 mice, 2 months old, were intraperitoneally
injected with dexamethasone (10mg/kg) dissolved in phosphate-
buffered saline. Control animals were injected with 150 ml of
phosphate-buffered saline. After 24 h, kidneys (n¼ 5 per group)
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were harvested and taken for isolation of glomeruli by using a
differential sieving method.
Statistical analysis
Statistical analysis was performed using either a two-tailed t-test or
one-way analysis of variance followed by Bonferroni’s post hoc test
for multiple comparisons (GraphPad, InStat version 3.00 for
Windows NT, GraphPad Software, San Diego, CA, USA).
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